查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971169

CAR-T細胞療法市場分析及預測（至2035年）：依類型、產品類型、服務、技術、應用、最終使用者、流程、階段、解決方案分類

CAR T Cell Therapy Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Stage, Solutions
出版日期: | 出版商: Global Insight Services | 英文 300 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計CAR-T細胞療法市場將從2024年的60億美元成長到2034年的218億美元，複合年成長率約為13.8%。 CAR-T細胞療法市場涵蓋嵌合體抗原受體T細胞療法的研發和商業化，該療法旨在靶向並摧毀癌細胞。該市場的特點是基因工程和個人化醫療領域的尖端進展。隨著癌症患者數量的增加和對創新治療方法需求的成長，提高療效、安全性和可近性成為推動市場成長的關鍵因素。主要趨勢包括生物技術公司與學術機構的合作、監管政策的發展以及全球臨床試驗的擴展。

CAR-T細胞療法市場正經歷強勁成長，這主要得益於免疫療法和個人化醫療的進步。骨髓惡性腫瘤領域主導市場，其中針對白血病和淋巴瘤等B細胞惡性腫瘤的療法在療效和普及率方面領先。固態腫瘤領域是第二大成長領域，在針對特定抗原方面取得了令人矚目的進展。在血液系統惡性腫瘤領域，CD19標靶治療特別突出，這主要得益於其在治療某些白血病和淋巴瘤方面的成功。 BCMA標靶治療領域也正在迅速發展，這反映了在對抗多發性骨髓瘤方面取得的顯著進展。在固態腫瘤領域，針對HER2和EGFR等抗原的治療方法進展顯著，並有望帶來突破性進展。正在進行的研究和臨床試驗正在擴大治療方法選擇，並凸顯創新方法在克服治療抗藥性方面的重要性。投資於生產能力和監管途徑對於擴大這些療法的規模、確保更廣泛的可及性和可負擔性至關重要。

市場區隔
類型 自體CAR-T細胞療法、異體CAR-T細胞療法
產品 Yeskata、Kymriah、Tekartas、Bryanji、Abekuma
服務 研發、生產製造、品管、法規遵循、臨床試驗、物流、諮詢
科技 基因編輯、慢病毒載體、CRISPR、睡美人轉座子
適應症 骨髓惡性腫瘤、固態腫瘤、非何傑金氏淋巴瘤、急性淋巴性白血病、多發性骨髓瘤、慢性淋巴性白血病
最終用戶 醫院、癌症治療中心、研究機構、生技公司、製藥公司
過程 細胞採集、細胞工程、細胞增生、品質檢測、冷凍保存
步 臨床前研究、臨床試驗與商業化
解決方案 病患監測、資料管理、供應鏈管理

市場概況：

CAR-T細胞療法市場正經歷動態變化，市場佔有率、定價策略和產品發布方面均取得了顯著進展。豐富的創新治療方法研發管線和對具有競爭力的定價策略的策略性關注是該市場的關鍵特徵。主要企業正在推出新型治療方法並強化其產品組合，以佔據更大的市場佔有率。此外，聯盟和夥伴關係正在增強競爭優勢並推動市場成長。在競爭方面，該市場的特徵是主要製藥公司之間的激烈競爭。基準分析顯示，各公司正在利用先進技術來保持其競爭優勢。法規結構，尤其是在北美和歐洲，對塑造市場動態至關重要。這些法規確保了藥物的安全性和有效性，並影響企業的市場准入和擴大策略。在技​​術進步、癌症發病率上升以及對個人化醫療日益成長的需求的推動下，該市場蓄勢待發，即將迎來成長。儘管高昂的治療成本和監管障礙等挑戰依然存在，但創新潛力依然巨大。

主要趨勢和促進因素：

CAR-T細胞療法市場正經歷強勁成長，這主要得益於基因工程和免疫療法的進步。關鍵趨勢包括開發具有更高特異性和更低毒性的新一代CAR-T細胞。生產流程的創新降低了成本，使更多患者能夠獲得治療。此外，監管支持和加速核准計劃正在加速新型治療方法的市場推廣。癌症和骨髓惡性腫瘤發生率的上升是關鍵促進因素，增加了對有效治療方法的需求。生物技術公司和研究機構之間的合作正在促進創新，並推動新型CAR-T細胞產品的開發。 CAR-T細胞療法在腫瘤治療領域之外的適應症拓展以及在自體免疫感染疾病的應用都蘊藏著巨大的潛力。預計對研發投入的增加將帶來變革性治療方法，從而推動CAR-T細胞療法市場持續成長，並顯著改善患者照護。

限制與挑戰：

CAR-T細胞療法市場面臨許多重大限制和挑戰。其中一個關鍵挑戰是CAR-T細胞療法的高昂費用，這限制了許多患者的治療機會。高成本源自於複雜的生產過程和個人化的治療方案。監管障礙也構成重大障礙，要求治療方法必須經過嚴格的測試和核准程序，從而延長了上市時間。此外，能夠管理和管理這些先進治療方法的專業人員短缺也限制市場發展。這種短缺影響了CAR-T細胞療法的擴充性和廣泛普及。此外，還存在嚴重副作用的風險，例如細胞激素釋放症候群，這可能會讓患者和醫療服務提供者望而卻步。最後，供應鏈中的物流挑戰，例如對精確溫度控制和及時交付的需求，也使CAR-T細胞療法的分銷變得複雜。所有這些因素共同阻礙了市場成長和普及。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 自體CAR-T細胞療法
    • 同種異體CAR-T細胞療法
  • 市場規模及預測：依產品分類
    • 耶斯卡塔
    • 凱姆裡亞
    • Tekartas
    • 布里安吉
    • 阿別隈
  • 市場規模及預測：依服務分類
    • 研究與開發
    • 製造業
    • 品管
    • 監理合規
    • 臨床試驗
    • 後勤
    • 諮詢
  • 市場規模及預測：依技術分類
    • 基因編輯
    • 慢病毒載體
    • CRISPR
    • 睡美人轉座子
  • 市場規模及預測：依應用領域分類
    • 骨髓惡性腫瘤
    • 固體癌
    • 非何傑金氏淋巴瘤
    • 急性淋巴性白血病
    • 多發性骨髓瘤
    • 慢性淋巴性白血病
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 癌症治療中心
    • 研究所
    • 生技公司
    • 製藥公司
  • 市場規模及預測：依製程分類
    • 細胞收集
    • 細胞工程
    • 細胞增殖
    • 品質檢測
    • 冷凍保存
  • 市場規模及預測：依階段分類
    • 臨床前階段
    • 臨床試驗
    • 商業化
  • 市場規模及預測：按解決方案分類
    • 病患監測
    • 資料管理
    • 供應鏈管理

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Legend Biotech
  • Autolus Therapeutics
  • Cellectis
  • Poseida Therapeutics
  • Tessa Therapeutics
  • Adaptimmune Therapeutics
  • Kite Pharma
  • Allogene Therapeutics
  • Caribou Biosciences
  • Cabaletta Bio
  • Immatics
  • Atara Biotherapeutics
  • Genocea Biosciences
  • Sorrento Therapeutics
  • Precision BioSciences

第9章：關於我們

簡介目錄
Product Code: GIS33699

CAR T Cell Therapy Market is anticipated to expand from $6 billion in 2024 to $21.8 billion by 2034, growing at a CAGR of approximately 13.8%. The CAR T Cell Therapy Market encompasses the development and commercialization of chimeric antigen receptor T-cell therapies, which are engineered to target and destroy cancer cells. This market is characterized by cutting-edge advancements in genetic engineering and personalized medicine. The increasing prevalence of cancer and the demand for innovative treatments are propelling growth, with a focus on improving efficacy, safety, and accessibility. Key trends include collaborations between biotech firms and academic institutions, regulatory advancements, and the expansion of clinical trials globally.

The CAR T Cell Therapy Market is experiencing robust growth, propelled by advancements in immunotherapy and personalized medicine. The segment focusing on hematological malignancies dominates, with therapies targeting B-cell malignancies such as leukemia and lymphoma leading in efficacy and adoption. Solid tumors represent the second highest performing segment, showcasing promising developments in targeting specific antigens. Within the hematological segment, the sub-segment of CD19-targeted therapies is particularly prominent, driven by their success in treating certain leukemias and lymphomas. The sub-segment addressing BCMA-targeted therapies is gaining momentum, reflecting significant strides in combating multiple myeloma. In the solid tumor segment, advancements in targeting antigens like HER2 and EGFR are notable, offering potential breakthroughs. Ongoing research and clinical trials are expanding the therapeutic landscape, underscoring the importance of innovative approaches in overcoming treatment resistance. Investment in manufacturing capabilities and regulatory pathways is crucial to scaling these therapies, ensuring broader access and affordability.

Market Segmentation
TypeAutologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy
ProductYescarta, Kymriah, Tecartus, Breyanzi, Abecma
ServicesResearch and Development, Manufacturing, Quality Control, Regulatory Compliance, Clinical Trials, Logistics, Consulting
TechnologyGene Editing, Lentiviral Vectors, CRISPR, Sleeping Beauty Transposon
ApplicationHematologic Malignancies, Solid Tumors, Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Multiple Myeloma, Chronic Lymphocytic Leukemia
End UserHospitals, Cancer Treatment Centers, Research Institutes, Biotechnology Companies, Pharmaceutical Companies
ProcessCell Collection, Cell Engineering, Cell Expansion, Quality Testing, Cryopreservation
StagePreclinical, Clinical Trials, Commercialization
SolutionsPatient Monitoring, Data Management, Supply Chain Management

Market Snapshot:

The CAR T Cell Therapy market is witnessing a dynamic shift with significant advancements in market share, pricing strategies, and product launches. The market is characterized by a robust pipeline of innovative therapies and a strategic focus on competitive pricing. Key players are introducing novel treatments, enhancing their portfolios to capture larger market segments. The landscape is further enriched by collaborations and partnerships, fostering a competitive edge and driving growth. In terms of competition, the market is marked by intense rivalry among leading pharmaceutical companies. Benchmarking reveals that companies are leveraging advanced technologies to maintain competitive advantages. Regulatory frameworks, particularly in North America and Europe, are pivotal in shaping market dynamics. These regulations ensure safety and efficacy, influencing market entry and expansion strategies. The market is poised for growth, driven by technological advancements, increasing prevalence of cancer, and rising demand for personalized medicine. Challenges such as high treatment costs and regulatory hurdles persist, yet the potential for innovation remains substantial.

Geographical Overview:

The CAR T Cell Therapy market is witnessing notable expansion across various regions, each demonstrating unique growth dynamics. North America remains at the forefront, propelled by pioneering research and substantial investments in biotechnology. The presence of leading pharmaceutical companies and advanced healthcare infrastructure further bolsters the market. Europe follows, with robust research initiatives and favorable regulatory frameworks fostering innovation in CAR T Cell Therapy. The region's commitment to personalized medicine enhances its market position. In Asia Pacific, the market is burgeoning, driven by increased healthcare spending and technological advancements. Countries like China and Japan are emerging as key players, investing heavily in research and development. Latin America and the Middle East & Africa are increasingly recognizing the potential of CAR T Cell Therapy. In Latin America, growing healthcare awareness and infrastructure improvements are driving market growth. Meanwhile, the Middle East & Africa are focusing on strategic collaborations to enhance their capabilities in this transformative therapy.

Key Trends and Drivers:

The CAR T Cell Therapy Market is experiencing robust growth fueled by advancements in genetic engineering and immunotherapy. Key trends include the development of next-generation CAR T cells, which are designed to enhance specificity and reduce toxicity. Innovations in manufacturing processes are driving down costs, making therapies more accessible to a broader patient base. Furthermore, regulatory support and fast-track approvals are accelerating the introduction of new therapies into the market. The rising prevalence of cancer and hematological malignancies is a significant driver, increasing demand for effective treatment options. Collaborations between biotech companies and research institutions are fostering innovation, leading to the development of novel CAR T cell products. Opportunities are abundant in expanding the therapeutic indications beyond oncology, exploring applications in autoimmune diseases and infectious diseases. The growing investments in research and development are expected to yield transformative therapies, positioning the CAR T Cell Therapy Market for sustained growth and substantial advancements in patient care.

Restraints and Challenges:

The CAR T Cell Therapy Market faces several significant restraints and challenges. A primary challenge is the exorbitant cost associated with CAR T cell therapies, which limits accessibility for many patients. This high cost stems from complex manufacturing processes and personalized treatment regimens. Regulatory hurdles also pose a significant barrier, as therapies must undergo rigorous testing and approval procedures, prolonging time to market. Moreover, the market is constrained by a lack of skilled professionals who can administer and manage these advanced therapies. This shortage impacts the scalability and widespread adoption of CAR T cell treatments. Additionally, there is a risk of severe side effects, including cytokine release syndrome, which can deter patients and healthcare providers. Finally, logistical challenges in the supply chain, such as the need for precise temperature control and timely delivery, complicate the distribution of CAR T cell therapies. These factors collectively impede market growth and accessibility.

Key Players:

Legend Biotech, Autolus Therapeutics, Cellectis, Poseida Therapeutics, Tessa Therapeutics, Adaptimmune Therapeutics, Kite Pharma, Allogene Therapeutics, Caribou Biosciences, Cabaletta Bio, Immatics, Atara Biotherapeutics, Genocea Biosciences, Sorrento Therapeutics, Precision BioSciences

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Autologous CAR T Cell Therapy
    • 4.1.2 Allogeneic CAR T Cell Therapy
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Yescarta
    • 4.2.2 Kymriah
    • 4.2.3 Tecartus
    • 4.2.4 Breyanzi
    • 4.2.5 Abecma
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Research and Development
    • 4.3.2 Manufacturing
    • 4.3.3 Quality Control
    • 4.3.4 Regulatory Compliance
    • 4.3.5 Clinical Trials
    • 4.3.6 Logistics
    • 4.3.7 Consulting
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Gene Editing
    • 4.4.2 Lentiviral Vectors
    • 4.4.3 CRISPR
    • 4.4.4 Sleeping Beauty Transposon
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Hematologic Malignancies
    • 4.5.2 Solid Tumors
    • 4.5.3 Non-Hodgkin Lymphoma
    • 4.5.4 Acute Lymphoblastic Leukemia
    • 4.5.5 Multiple Myeloma
    • 4.5.6 Chronic Lymphocytic Leukemia
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Cancer Treatment Centers
    • 4.6.3 Research Institutes
    • 4.6.4 Biotechnology Companies
    • 4.6.5 Pharmaceutical Companies
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Cell Collection
    • 4.7.2 Cell Engineering
    • 4.7.3 Cell Expansion
    • 4.7.4 Quality Testing
    • 4.7.5 Cryopreservation
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Preclinical
    • 4.8.2 Clinical Trials
    • 4.8.3 Commercialization
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Patient Monitoring
    • 4.9.2 Data Management
    • 4.9.3 Supply Chain Management

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Stage
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Stage
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Stage
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Stage
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Stage
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Stage
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Stage
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Stage
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Stage
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Stage
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Stage
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Stage
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Stage
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Stage
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Stage
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Stage
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Stage
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Stage
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Stage
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Stage
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Stage
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Stage
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Stage
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Stage
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Legend Biotech
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Autolus Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Cellectis
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Poseida Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Tessa Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Adaptimmune Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Kite Pharma
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Allogene Therapeutics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Caribou Biosciences
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Cabaletta Bio
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Immatics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Atara Biotherapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Genocea Biosciences
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Sorrento Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Precision BioSciences
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us